Cooper Companies, Inc.

Company facts

Industry

Ophthalmic Goods

Headquarters

San Ramon, California

Most recent report

10-Q, filed Sep 9, 2026

Incorporated

Delaware

Filings on record

1,008+ filings

On EDGAR

CIK 711404

Fiscal year ends

October

Filer status

Large accelerated filer

What to read: Jul 2026 10-Q

SECSift found 3 of 13 sections worth reading, with 1 positive, 3 notable, and 3 negative flags.

• Financial Statements (Item 1)

  Core financials show large litigation charge, debt maturity wall, and $307M tax benefit masking earnings.
  Notable

  • $307.2M discrete tax benefit from releasing uncertain tax position after UK tax examination closed favorably in June 2026.
  • HMRC tax dispute could cost up to £71.7M plus interest; company is appealing.
  Negative

  • CooperSurgical litigation accrued $316.5M liability; $272M net charge in nine months 2026.
  • CooperSurgical nine-month operating loss $157.1M vs $39.7M profit prior year.

• Legal Proceedings (Item 1)

  Material litigation with $272M charge and $307M paid post-quarter.
  Notable

  • UK tax dispute on Sauflon acquisition: HMRC largely won at tribunal; potential loss up to £71.7M.
  Negative

  • $272.0M net charge from embryo media claims; $306.8M paid in Aug 2026, ongoing exposure.

• Unregistered Sales and Repurchases (Item 2)

  Large buyback authorization increase to $3.0B and significant Q3 repurchases of 4.9M shares.
  Positive

  • Buyback authorization raised by $1.0B to $3.0B in Sep 2026, leaving ~$1.5B available.

What changed: Jul 2026 vs. Apr 2026

About 7% of COO's Jul 2026 10-Q is new information. 22 paragraphs were added, 94 changed, and 14 removed. Below are the most important lines SECSift identified.

• Item 1 82
• Item 6 7
• Item 2 4
• Item 3 2
• Item 4 2
• Item 5 1